- Home
- AMRN vs INFU Comparison
AMRN vs INFU Comparison
Compare AMRN & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- INFU
- Stock Information
- Founded
- AMRN 1989
- INFU 2005
- Country
- AMRN Ireland
- INFU United States
- Employees
- AMRN N/A
- INFU N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- INFU Medical/Dental Instruments
- Sector
- AMRN Health Care
- INFU Health Care
- Exchange
- AMRN Nasdaq
- INFU Nasdaq
- Market Cap
- AMRN 216.0M
- INFU 104.4M
- IPO Year
- AMRN 1993
- INFU N/A
- Fundamental
- Price
- AMRN $15.80
- INFU $5.52
- Analyst Decision
- AMRN Strong Sell
- INFU
- Analyst Count
- AMRN 1
- INFU 0
- Target Price
- AMRN $12.00
- INFU N/A
- AVG Volume (30 Days)
- AMRN 172.9K
- INFU 276.5K
- Earning Date
- AMRN 07-30-2025
- INFU 08-07-2025
- Dividend Yield
- AMRN N/A
- INFU N/A
- EPS Growth
- AMRN N/A
- INFU 3654.89
- EPS
- AMRN N/A
- INFU 0.15
- Revenue
- AMRN $214,112,000.00
- INFU $137,582,000.00
- Revenue This Year
- AMRN N/A
- INFU $11.08
- Revenue Next Year
- AMRN N/A
- INFU $8.02
- P/E Ratio
- AMRN N/A
- INFU $36.96
- Revenue Growth
- AMRN N/A
- INFU 7.98
- 52 Week Low
- AMRN $7.08
- INFU $4.61
- 52 Week High
- AMRN $17.49
- INFU $9.97
- Technical
- Relative Strength Index (RSI)
- AMRN 60.01
- INFU 39.73
- Support Level
- AMRN $16.12
- INFU $5.55
- Resistance Level
- AMRN $17.49
- INFU $6.31
- Average True Range (ATR)
- AMRN 0.78
- INFU 0.25
- MACD
- AMRN -0.13
- INFU -0.09
- Stochastic Oscillator
- AMRN 34.42
- INFU 11.73
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.